Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma.

Bähr O, Harter PN, Weise LM, You SJ, Mittelbronn M, Ronellenfitsch MW, Rieger J, Steinbach JP, Hattingen E.

Neurology. 2014 Jul 15;83(3):227-34. doi: 10.1212/WNL.0000000000000594. Epub 2014 Jun 13.

PMID:
24928118
[PubMed - in process]
2.

Confounding factors in diagnostics of MGMT promoter methylation status in glioblastomas in stereotactic biopsies.

Weise LM, Harter PN, Eibach S, Braczynski AK, Dunst M, Rieger J, Bähr O, Hattingen E, Steinbach JP, Plate KH, Seifert V, Mittelbronn M.

Stereotact Funct Neurosurg. 2014;92(3):129-39. doi: 10.1159/000360582. Epub 2014 Apr 24.

PMID:
24776650
[PubMed - in process]
3.

Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid.

Fischer S, Ronellenfitsch MW, Thiepold AL, Harter PN, Reichert S, Kögel D, Paschke R, Mittelbronn M, Weller M, Steinbach JP, Fulda S, Bähr O.

PLoS One. 2014 Apr 17;9(4):e94921. doi: 10.1371/journal.pone.0094921. eCollection 2014.

PMID:
24743710
[PubMed - in process]
Free PMC Article
4.

ERGO: a pilot study of ketogenic diet in recurrent glioblastoma.

Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M, Steinbach JP.

Int J Oncol. 2014 Jun;44(6):1843-52. doi: 10.3892/ijo.2014.2382. Epub 2014 Apr 11.

PMID:
24728273
[PubMed - in process]
Free PMC Article
5.

Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.

Hattingen E, Jurcoane A, Daneshvar K, Pilatus U, Mittelbronn M, Steinbach JP, Bähr O.

Neuro Oncol. 2013 Oct;15(10):1395-404. doi: 10.1093/neuonc/not105. Epub 2013 Aug 7.

PMID:
23925453
[PubMed - indexed for MEDLINE]
6.

MR perfusion in and around the contrast-enhancement of primary CNS lymphomas.

Blasel S, Jurcoane A, Bähr O, Weise L, Harter PN, Hattingen E.

J Neurooncol. 2013 Aug;114(1):127-34. doi: 10.1007/s11060-013-1161-z. Epub 2013 May 22.

PMID:
23695516
[PubMed - indexed for MEDLINE]
7.

Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy.

Hattingen E, Bähr O, Rieger J, Blasel S, Steinbach J, Pilatus U.

PLoS One. 2013;8(3):e56439. doi: 10.1371/journal.pone.0056439. Epub 2013 Mar 8.

PMID:
23520454
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Synthesis of cytochrome C oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death.

Wanka C, Brucker DP, Bähr O, Ronellenfitsch M, Weller M, Steinbach JP, Rieger J.

Oncogene. 2012 Aug 16;31(33):3764-76. doi: 10.1038/onc.2011.530. Epub 2011 Nov 28.

PMID:
22120717
[PubMed - indexed for MEDLINE]
9.

Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial.

Bähr O, Hermisson M, Rona S, Rieger J, Nussbaum S, Körtvelyessy P, Franz K, Tatagiba M, Seifert V, Weller M, Steinbach JP.

Acta Neurochir (Wien). 2012 Feb;154(2):229-35; discussion 235. doi: 10.1007/s00701-011-1144-9. Epub 2011 Sep 10.

PMID:
21909835
[PubMed - indexed for MEDLINE]
10.

Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study.

Hattingen E, Jurcoane A, Bähr O, Rieger J, Magerkurth J, Anti S, Steinbach JP, Pilatus U.

Neuro Oncol. 2011 Dec;13(12):1349-63. doi: 10.1093/neuonc/nor132. Epub 2011 Sep 2.

PMID:
21890539
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma.

Bähr O, Hattingen E, Rieger J, Steinbach JP.

Neuro Oncol. 2011 Sep;13(9):1020-9. doi: 10.1093/neuonc/nor099. Epub 2011 Jul 31.

PMID:
21807668
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy.

Maurer GD, Brucker DP, Bähr O, Harter PN, Hattingen E, Walenta S, Mueller-Klieser W, Steinbach JP, Rieger J.

BMC Cancer. 2011 Jul 26;11:315. doi: 10.1186/1471-2407-11-315.

PMID:
21791085
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.

Glas M, Bähr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, Simon M, Urbach H, Steinbach JP, Rieger J, Fimmers R, Bamberg M, Nägele T, Reifenberger G, Weller M, Herrlinger U; Neuro-Oncology Group of the German Cancer Society.

Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub 2011 Jun 27.

PMID:
21710625
[PubMed - indexed for MEDLINE]
14.

Complementary therapy use in patients with glioma: an observational study.

Heese O, Schmidt M, Nickel S, Berger H, Goldbrunner R, Tonn JC, Bähr O, Steinbach JP, Simon M, Schramm J, Krex D, Schackert G, Reithmeier T, Nikkhah G, Löffler M, Weller M, Westphal M; German Glioma Network.

Neurology. 2010 Dec 14;75(24):2229-35. doi: 10.1212/WNL.0b013e31820202c6.

PMID:
21172846
[PubMed - indexed for MEDLINE]
15.

Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?

Rieger J, Bähr O, Ronellenfitsch MW, Steinbach J, Hattingen E.

J Clin Oncol. 2010 Sep 20;28(27):e477; author reply e478. doi: 10.1200/JCO.2010.29.2029. Epub 2010 Jun 28. No abstract available.

PMID:
20585096
[PubMed - indexed for MEDLINE]
16.

Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients.

Rieger J, Bähr O, Müller K, Franz K, Steinbach J, Hattingen E.

J Neurooncol. 2010 Aug;99(1):49-56. doi: 10.1007/s11060-009-0098-8. Epub 2009 Dec 25.

PMID:
20035366
[PubMed - indexed for MEDLINE]
17.

Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.

Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bähr O, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W.

Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):670-6. doi: 10.1016/j.ijrobp.2009.05.031. Epub 2009 Oct 14.

PMID:
19836157
[PubMed - indexed for MEDLINE]
18.

Very late relapses in glioblastoma long-term survivors.

Bähr O, Herrlinger U, Weller M, Steinbach JP.

J Neurol. 2009 Oct;256(10):1756-8. doi: 10.1007/s00415-009-5167-6. Epub 2009 May 12.

PMID:
19434438
[PubMed - indexed for MEDLINE]
19.

Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.

Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W, Kortmann RD, Reifenberger G, Weller M, Herrlinger U.

J Clin Oncol. 2009 Mar 10;27(8):1257-61. doi: 10.1200/JCO.2008.19.2195. Epub 2009 Feb 2.

PMID:
19188676
[PubMed - indexed for MEDLINE]
20.

Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice.

Naumann U, Bähr O, Wolburg H, Altenberend S, Wick W, Liston P, Ashkenazi A, Weller M.

Gene Ther. 2007 Jan;14(2):147-61. Epub 2006 Sep 7. Erratum in: Gene Ther. 2007 Oct;14(19):1434-7.

PMID:
16957768
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk